Abstract

Now that there are several effective treatments for the acute inflammatory phase of multiple sclerosis, the unmet need is therapies which will prevent demyelination and neuronal loss, or that will promote remyelination.

I will review the pathological processes involved in oligodendrocyte and neuronal loss, and failure of remyelination, and highlight some targets for intervention.

I will also review the high throughput models available for drug screening.